Diaceutics Issues New Shares to Trust as PDMRs Participate in Incentive Plan

Diaceutics ( (GB:DXRX) ) has provided an update.

Diaceutics PLC has disclosed that trustees of its 2020 Employee Benefit Trust have purchased ordinary shares on behalf of three senior executives under the company’s UK and Global Share Incentive Plan, with the company matching these purchases on a 1:1 basis through conditional share awards. To facilitate these awards, Diaceutics issued 4,848 new shares to the UK trust, drawn from a previously established block listing, bringing the total number of shares in issue to 84,917,283 and providing clarity for investors on the company’s capital structure and voting rights while underscoring the use of equity-based incentives to align management and employee interests with shareholders.

The most recent analyst rating on (GB:DXRX) stock is a Sell with a £160.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.

Spark’s Take on GB:DXRX Stock

According to Spark, TipRanks’ AI Analyst, GB:DXRX is a Neutral.

Diaceutics’ strong revenue growth and positive corporate events are overshadowed by challenges in profitability, cash flow, and bearish technical indicators. The stock’s valuation is also concerning due to negative earnings.

To see Spark’s full report on GB:DXRX stock, click here.

More about Diaceutics

Diaceutics PLC is a technology and solutions provider to the global pharma and biotech industry, focusing on accelerating the commercialisation of precision medicines. Through its DXRX – The Diagnostics Network platform, alongside data analytics and scientific and advisory services, the company helps leading drug developers ensure patients receive the right diagnostic tests and targeted therapies to improve disease outcomes.

Average Trading Volume: 123,800

Technical Sentiment Signal: Buy

Current Market Cap: £143.8M

Find detailed analytics on DXRX stock on TipRanks’ Stock Analysis page.